Shilpa Medicare Limited (BOM: 530549)
India
· Delayed Price · Currency is INR
873.80
+12.85 (1.49%)
At close: Oct 11, 2024
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 2.93B INR in the quarter ending June 30, 2024, with 12.43% growth. This brings the company's revenue in the last twelve months to 11.84B, up 12.85% year-over-year. In the fiscal year ending March 31, 2024, Shilpa Medicare had annual revenue of 11.53B with 9.64% growth.
Revenue (ttm)
11.84B
Revenue Growth
+12.85%
P/S Ratio
6.63
Revenue / Employee
11.76M
Employees
1,007
Market Cap
75.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
Mar 31, 2020 | 9.08B | 1.75B | 23.79% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionShilpa Medicare News
- 9 days ago - Shilpa Medicare shares surge over 2% after arm gets CEP from EDQM for Desmopressin - Business Upturn
- 10 days ago - Shilpa Pharma Lifesciences receives CEP for Desmopressin from EDQM - Business Upturn
- 10 days ago - Shilpa Pharma Lifesciences gets certificate of suitability from EDQM for API, Desmopressin - Business Upturn
- 24 days ago - Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as new CEO - Business Upturn
- 27 days ago - Shilpa Medicare shares rise 4% to after Antique initiates ‘Buy’ rating with target price of ₹1300 - Business Upturn
- 6 weeks ago - Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection - Business Upturn
- 6 weeks ago - Shilpa Medicare surges over 5% on USFDA approval for Bortezomib Injection - Business Upturn
- 6 weeks ago - Shilpa Medicare gets USFDA approval for Bortezomib Injection - Business Upturn